Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up  by Coen, Giorgio et al.
Kidney International, Vol. 28 (1985), PP. 783—790
CLINICAL INVESTIGATION
Bone GLA protein in predialysis chronic renal failure.
Effects of 1 ,25(OH)2D3 administration in a long-term follow-up
GI0RGI0 COEN, SANDRO MAZZAFERRO, ERMANNO BoNuccl, FRANCO TAGGI,
PAOLA BALLANTI, ANNA R. BIANcHI, GIUSEPPE DONATO, CARLO MASSIMETTI,
ANTONELLA SMACCHI, and GluLlo A. CIN0TTI
Division of Nephrology, Second Medical Clinic and Department of Human Biopathology, University La Sapienza,
and Istituto Superiore di Sanità, Rome, Italy
Bone GLA protein in predialysis chronic renal failure. Effects of
1,25(011)21)3 adminIstration In a long-term follow-up. Serum bone GLA
protein (BGP) was measured by radioimmunoassay in 42 patients (age,
47.5 16.6 years; serum creatinine, 4.32 1.9 mg/dl) with predialysis
chronic renal failure (CRF). Nineteen patients were studied within a
short period of time, while 23 were followed with repeated measure-
ments of serum BGP, creatinine, iPTH, and alkaline phosphatase (AP)
for a mean period of 17.1 8.1 months. Eleven of these patients were
treated with 1,25(OH)2D3 for a mean of 16.8 6.4 months. In 23
patients at various stages of CRF, a transiliac bone biopsy was
performed for histomorphometnc evaluation. In the untreated patients,
serum BGP was higher than normal and showed a positive correlation
with creatinine levels (P < 0.001). Serum BGP was also positively
correlated with iPTH, AP, serum phosphate, active resorption surface,
active osteoblastic surface, osteoid surface, and volume. During treat-
ment with 1,25(OH)2D3, BGP, iPTH, and AP were significantly lower
than in the untreated patients. The reduction in iPTH and BGP was
proportional, while BOP and AP no longer correlated. Repeated mea-
surements of BGP during the long-term follow-up showed a progressive
rise in the untreated patients and a downward course of BGP levels
during treatment. In conclusion, serum BGP increases progressively in
CRF, rising with advancing renal damage in close correlation with
iPTH, AP, and the severity of renal osteodystrophy. Treatment with
1 ,25(OH)2D, causes a parallel decline in BGP and iPTH levels and
dissociation between BGP and AP can be observed. Compared to AP,
BOP seems to be a more reliable index of secondary hyperpara-
thyroidism and potentially more useful in the long-term monitoring of
treatment with 1 ,25(OH)2D3.
GLA protéine osseuse au cours de l'insuffisance rénale chronique
prédlalytique. Effets de l'administratlon de 1,25(OH)2D3 au cows d'une
étude a long terme. La GLA protéine osseuse sérique (BGP) a été
mesurée par dosage radioimmunologique chez 42 malades (age 47,5
16,6 ans; créatininémie 4,32 1,9 mg/dl) en insuffisance rénale
chronique prédialytique (CRF). Dix-neuf malades ont été étudiés pen-
dant une courte période de temps, tandis que 23 autres ont suivis
avec des mesures répétées de BGP, de créatinine, d'iPTH et de
phosphatase alcaline (AP) sriques pendant une période moyenne de
17,1 8,1 mois. Onze de ces malades ont été traités avec du
I ,25(OH)2D3 pendant 16,8 6,4 mois en moyenne. Chez 23 malades a
des degrés divers de CRF, une biopsie osseuse transiliaque a été
effectuée en vue d'une evaluation histomorphometrique. Chez les
malades non traitds, Ia BGP sCrique Ctait plus ClevCe que chez
lesnormaux, et était positivement corrClCe avec les niveaux de
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crCatinine (P < 0,001). La BGP sCrique Ctait egalement positivement
corrClCe avec iPTH, AP, Ia phosphatCmie, Ia surface de resorption
active, la surface ostCoblastique active, Ia surface ostCoide et le
volume. Pendant le traitement avec 1,25(OH)2D3, BGP, iPTH et AP
Ctaient significativement plus faibles que chez les malades non traitCs.
La reduction d' iVFH et de BGP était proportionnelle, alors que BGP et
AP ne restaient plus corrClCs. Des mesures rCpétCes de BGP pendant le
suivi a long terme ont rCvClC une augmentation progressive chez les
malades non traitCs, et un abaissement des niveaux de BGP au cours du
traitement. En conclusion, Ia BGP sérique s'ClCve progressivement au
cours de CRF, augmentant avec la progression des lesions rCnales de
facon Ctroitement corrélCe avec iPTH, AP et la sCvCritC de
l'ostCodystrophie rCnale. Le traitement par 1,25(OH)2D, entraine une
diminution parallCle de BGP et des mveaux d' 1PI'H, et une dissociation
entre BGP et AP peut Ctre observCe. Par rapport a AP, BGP semble un
index plus fiable d'hyperparathyroidisme secondaire, et potentiellement
plus utile pour Ia surveillance a long terme du traitement par
1 ,25(OH)2D3.
Osteocalcin, or bone GLA protein (BGP), is a vitamin
K-dependent protein of bone with 49 aminoacids that contains
three y-carboxyglutamic acid residues. BGP is the most abun-
dant (25%) non-collagenous protein of bone [1]. Small concen-
trations of this protein are found also in the serum and are
detectable by radioimmunoassay [2]. In the last few years, BGP
has been found to be endowed with a rather selective binding
affinity for insoluble Ca salts, especially hydroxyapatite
crystals, presumably through the GLA residues [3]. In addition,
BGP can be detected in embryonic bone tissue from the
beginning of the mineralization process [4]. Therefore, BGP
might be involved in the mechanism of mineralization of the
osteoid matrix. There is experimental evidence that BGP is
synthesized by the osteoblasts [5], and the circulating levels of
BGP probably reflect the osteoblastic activity in protein syn-
thesis and the rate of bone formation. BGP production by the
osteoblasts seems to be strictly dependent on the levels of
1 ,25(OH)2D3 in vitro [61. Nonetheless, in predialytic chronic
renal failure (CRF), in spite of the known defect in 1 ,25(OH)2D3
synthesis [7], serum levels of BGP are elevated and closely
correlated to serum iPTH levels [8]. As the increment in BGP
does not seem to be explained by decreased renal ifitration
alone [91, other factors besides the vitamin D metabolites may
possibly regulate the synthesis of BGP.
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alkaline phosphatase (AP) serum measurements provide equiv-
alent indication of osteoblastic activity.
The aim of this study was to explore the natural evolution of
serum BGP levels in predialytic CRF, to examine the relation-
ship between BGP and other biochemical and bone histomor-
phometric parameters, and to establish the role of serial mea-
surements of serum BGP in the long-term treatment of predial-
ysis CRF with 1 ,25(OH)2D3.
Methods
Patients
A total of 42 patients with CRF from the outpatient renal
clinic of the Division of Nephrology, Policlinico Umberto I of
Rome, was studied. There were 25 males and 17 females, with
a mean age of 47.5 16.6 (M, SD) years (range, 12 to 73). All the
patients showed a slow decline of renal function while being
followed in the renal clinic and/or in the retrospective analysis
of serial serum creatinine values. The presumed clinical diag-
noses were: 23 patients with chronic glomerulonephritis, 12
with chronic pyelonephritis, three with polycystic kidney dis-
ease, one with medullary cystic disease (the only patient of
adolescent age), and three patients with unknown causes of
CRF. Serum creatinine levels ranged from 1.5 to 9 mg/dl (4.32
1.9 mgldl). Nineteen patients were studied within a short
period of time, while 23 patients (44.8 18.9 years; serum
creatinine, 4.25 1.5 mg/dl) were followed with repeated
measurements of serum creatinine, iPTH, AP, and BGP in the
outpatient clinic for a mean time of 17.1 8.1 months. Eleven
of these patients (54.1 15.3 years; serum creatinine, 4.26
1.3 mg/dl), after a short period of study for the evaluation of
basal humoral parameters, were treated with daily doses of 0.25
g of 1,25(OH)2D3 for a mean of 16.8 6.4 months. The dose
of 1 ,25(OH)2D3 was selected with the aim of avoiding hypercal-
cemia and renal damage [101 and at the same time effectively
controlling secondary hyperparathyroidism. In a long-term
Cr, mg/dl 4.34 1.96 0.7 to 1.1
Ca, mg/d! 9.12 0.72 9.0 to 10.4
P, mg/dl 4.10 0.95 2.8 to 4.5
iPTH, ng/ml 1.94 2.09 0.1 to 0.7
AP, mpJml 183.21 115.95 70.0 to 160.0
BOP, ng/ml 17.35 21.44 1.8 to 8.4
Mean 5D.
study carried out on patients with CRF [11], the dose of 0.25 j.g
daily or an equivalent dose of laOHD3, was able to fulfill these
aims, at least for most of the time course of decline toward
levels.
In 23 patients at various stages of renal damage (serum
creatinine 6.4 2.25 mg/dl, range 2.2 to 9.8) who did not
receive I ,25(OH)2D3, a transiliac bone biopsy was performed
for histomorphometric evaluation.
Assays
Serum BGP was measured by radioimmunoas say based on
the method of Price and Nishimoto [21. Purified calf BGP was
used as standard. This protein is immunologically identical to
human BGP [121. The antiserum was a rabbit anti-BGP anti-
body. Phase separation was accomplished with a goat antise-
rum to rabbit y-globulin and polyethylene glycol. The incuba-
tion mixture, 450 1d, was left overnight at 4°C in borosilicate
tubes. Following the addition of 500 pi of the precipitating
complex, centrifugation, and after discarding the supernatant,
the pellet containing '251-labeled BGP bound to rabbit antibody
was then assessed for radioactivity in a y-counter (Packard
Autogamma 500, Hewlett-Packard, Elkhart, Indiana, USA) for
a time sufficient to achieve a counting accuracy of < 3%.
Non-specific binding of radioactivity to the precipitate and to
the reaction tube was measured by incubating 1251-labeled BGP
and unknown sera without specific antiserum, and precipitating
with the usual second antibody technique. Serial dilutions of
unknown samples showed a decline in value parallel to the
standard curve (Fig. 1). The limit of detectability was < 0.3
ng/ml. The intraassay and interassay variations were respec-
tively lower than S and 8%. Since a circadian variation of serum
BOP levels with a morning fall in values is a known phenome-
non [13], blood samples were drawn from ambulatory patients,
at the same time of day, between 10 and 11 A.M. The samples
were stored at —30°C until the assay. The results obtained in 25
adult normal subjects (13 male and 12 female) gave an average
value of 3.89 1.45 ng/ml. These values are slightly lower than
those reported by other investigators [2, 9]. Circadian variation
and sampling time differences may account for the discrepancy.
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Table 1. Serum biochemical measurements in 42 patients with chronic
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Fig. 1. Radioimmunoassay of BGP showing similar reactivities of serial
concentrations of bovine BGP standard (0—0) and dilutions of un-
known serum sample (—I) from a patient with CRF (log-logit).
Another important issue is whether in CRF, BGP, and bone
0.1 1
_____
terminal renal insufficiency. However, our data do not exclude
s 10 that higher doses might be equally safe and more effective.
None of the patients was receiving corticosteroid, anti-
coagulant, or anticonvulsant medication. They were following a
diet regimen that, compared to the average Italian diet, was
moderately restricted in protein (0.8 g/kg body wt) and phos-
phorus (12 mg/kg body wt) and received calcium p.o., 500 mg
daily, as organic salts. None of the patients required at any time
aluminum hydroxide administration to control serum phosphate
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Table 2. Biochemical and histomorphometric data in 23 patients with predialytic chronic renal failure
Patient Serum chemistry Histomorphometry°
Age Cr Ca P AP PTH BGP TBV OV OS AOS RS ARS 01
Number years Sex rng/dl mg/dl mg/dl mU/mi ng/ml ng/mi % % % % % % TIO number/mm2
I 23 M 2.2 9.7 4.2 93 0.4 2.9 24.41 2.23 14.63 1.91 0.68 0.15 15.24 0.11
2 52 F 2.5 10.0 3.9 87 0.7 9.4 29.84 1.80 16.73 1.38 0.99 0.19 10.75 0.22
3 33 M 2.9 10.0 3.6 161 0.9 9.0 23.66 1.74 15.86 0.27 3.91 0.10 10.97 0.11
4 18 M 4.0 9.0 3.7 126 0.9 14.4 29.02 5.49 18.00 1.26 0,34 0.13 30.50 0.11
5 29 M 4.3 8.7 5.2 168 0.6 7.6 19.60 1.43 11.17 0.00 0.58 0.58 7.81 0.67
6 51 F 4.4 8.4 4.3 211 1.7 9.0 25.26 19.77 88.55 1.40 5.43 0.62 22.32 0.65
7 73 F 4.6 9.3 3.9 118 0.8 15.6 16.19 3.06 20.51 0.00 3.04 0.00 14.91 0.00
8 20 M 5.4 10.0 5.0 188 1.6 10.0 23.25 10.50 47.25 11.44 8.74 2.42 22.22 2.15
9 23 M 5.8 9.4 4.7 160 2.1 31.0 18.14 5.47 32.49 2.68 7.12 1.20 16.83 0.90
10 49 M 6.5 9.1 4.2 136 2.6 23.0 22.42 8.60 53.12 6.01 7.72 1.08 16.18 1.13
11 48 M 6.5 8.5 3.8 166 4.2 54.0 29.88 11.49 69.04 8.96 11.04 1.03 16.64 1.24
12 31 F 6.8 8.4 5.1 67 1.9 4.4 24.23 0.90 10.69 1.28 2.17 0.38 8.41 0.32
13 56 M 7.0 7.9 5.8 99 2.2 10.8 14.58 1.61 19.74 0.00 1.42 0.43 8.11 0.48
14 56 F 7.1 8.2 4.5 262 6.8 32.0 20.88 10.81 69.74 4.00 6.08 1.51 15.50 1.40
15 60 M 7.3 8.6 5.1 117 1.8 26.0 21.85 2.50 19.86 0.00 1.77 0.54 12.58 0.45
16 59 M 7.5 9.0 3.1 204 3.9 49.5 23.14 23.21 77.08 4.43 12.28 2,02 30.11 2.27
17 21 M 8.2 9.1 7.9 113 4.5 30.0 26.60 1.09 11.24 2.86 16.46 2.75 9.69 3.39
18 60 M 8.4 8.4 5.0 131 4.0 32.0 19.83 10.03 60.84 7.20 8.67 0.77 16.48 0.79
19 28 M 8.5 9.3 4.1 70 1.8 9.0 23.66 1.16 10.98 0.18 0.56 0.08 10.56 0.10
20 48 F 8.6 9.3 5.7 670 8.0 132.0 26.34 18.36 65.14 10.29 15.56 5.54 28.18 6.28
21 48 F 9.5 7.7 6.9 300 10.0 25.6 24.53 3.61 27.37 6.83 8.49 1.49 13.18 1.73
22 44 M 9.8 10.0 6.3 109 5.5 62.0 23.43 3.55 21.71 2.55 3.46 1.55 16.35 1.35
23 72 F 9.8 8.4 4.4 120 2.7 7.8 19.96 5,11 50.98 5.56 4.70 0.50 10.02 0.54
Mean 43.5 6.4 8.9 4.8 168 3.0 26.0 23.03 6.67 36.20 3.49 5.70 1.08 15.76 1.14
SD 16.8 2.2 0.6 1.1 123 2.5 28.5 3.96 6.47 25.13 3.49 4.80 1.23 6.75 1.40
Normal&' Mean 20.33 1.44 9.47 0.27 1.77 0.19 13.50 0.20
(N = 57) SD 4.67 1.24 7.30 0.64 1.50 0.30 4.93 0.22
Range 18.98 to
30.39
0.03 to
5.11
0.59 to
31.25
0.00 to
3.01
0.20 to
6.78
0.00 to
2.07
4.68 to
23.81
0.00 to
0.86
a For abbreviations, see Methods.
b Normal values for the biochemical parameters are reported in Table 1.
In five idiopathic and surgical hypoparathyroid patients and in
seven patients with primary hyperparathyroidism assessed by
surgery, serum BGP levels were 1.14 0.86 and 14.06 8.1
ng/ml, respectively.
Serum iPTH levels were measured by radioimmunoassay
based on a chicken antihuman parathyroid hormone serum,
directed against the 65-84 portion of the molecule. The standard
was a human synthetic PTH peptide (65-84). Phase separation
was accomplished with a rabbit antichicken y-globulin and
polyethylene glycol, following 24-hr incubation at 4°C. This
method is useful in patients with secondary hyperpara-
thyroidism of CRF. Serial dilutions of the sera with high levels
of the hormone give a linear decline parallel to the standard
curve. Standards and unknown sera were run in triplicate with
two dilution levels of the unknowns when iPTH levels were
higher than 3 ng/ml. Intraassay and interassay variations were
respectively 6 and 13.3%. Normal values expressed in terms of
mass of the intact human molecule are 0.34 0.19 ng/ml.
Serum 1 ,25(OH)2D3 was measured by the receptorial method
with the cytosol receptor from chicken duodenal mucosa as
described by Eisman et al [14]. Preliminary purification of the
sample following an extraction with acetonitrile was accom-
plished on Sep-pak Cl8 columns. After elution with acetoni-
trile, desiccation, and dissolution in hexane:isopropanol, the
sample was further purified on silica Sep-pak cartridges and on
direct phase silica HPLC columns (tPorasil, 10 j, Waters
Assoc. Inc., Milford, Massachusetts, USA) with hexane:
isopropanol as the mobile phase [15]. Normal serum levels are
34.8 10.2 pg/ml (range, 16 to 62). Intra- and interassay
variations were respectively 10 and 14.2%.
AP measurements were performed spectrophotometrically
using p-nitrophenyl phosphate as the substrate (Boehringer-
Biochemia, Mannheim, Federal Republic of Germany). The
normal range for the adult population is 70 to 160 mU/ml. Serum
levels of calcium were measured by atomic absorption spec-
trophotometry (Perkin Elmer, Model 300, Norwalk, Connecti-
cut USA). Serum creatinine and serum and urine phosphorus
were measured by autoanalyzer (Technicon Autoanalyzer RA
1000, Tarrytown, New York USA). The normal range for serum
calcium, creatinine, and phosphorus are reported in Table 1.
Transiiac bone biopsies were performed under local anesthe-
sia with a Bordier trocar with an internal diameter of 5 mm. The
sample was fixed in phosphate buffered (pH 7.2) 4% paralorm-
aldehyde. Other details of the histological procedure have been
reported previously [16]. Histomorphometne evaluation was
performed with a semiautomatic image analyzer (Videoplan
Kontron, Munich, Federal Republic of Germany).
The following parameters were evaluated: trabecular bone
volume (TBV), the percentage of the cancellous bone space
occupied by bone; osteoid volume (OV), the percentage of the
trabecular bone made of uncalcified bone matrix; osteoid sur-
face (OS), the percentage of trabecular surface covered by
osteoid; active osteoblastic surface (AOS), the percentage of
trabecular surface covered by osteoid lined by active
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osteoblasts; resorption surface (RS), the percentage of the total
surface consisting of Howship's lacunae; active resorption
surface (ARS), the percentage of the total bone surface under-
going resorption with visible osteoclasts; osteoclastic index
(01), the number of osteoclasts counted in a mm2 surface of the
bone section; thickness index of osteoid (TI0), the ratio be-
tween osteoid volume and osteoid surface. The normal values
for the parameters are reported in Table 2.
Statistical analysis
The data were statistically evaluated with programs of the
BMDP package from the University of Los Angeles [17] on an
IBM 4341 computer at the Istituto Superiore di Sanità.
Results
Basal biochemical measurements of the patients are summa-
nzed in Table 1. Serum BGP levels in 25 normal subjects and in
42 patients with CRF are reported in Figure 2. Multiple mea-
surements of BGP in some patients were carried out at different
2 4 6 8 10 12
Creatiruine, ng/dI
Fig. 3. Serum BGP levels as a function of serum creatinine. The
non-linear correlation is a parabolic function.
stages of renal insufficiency. Serum BCIP levels in CRF are
generally higher than in normal controls, with the higher levels
being found in the more advanced stages of renal failure. This
finding is illustrated by Figure 3, where BGP levels of patients
who did not receive l,25(OH)2D3 are reported against serum
creatinine levels. The changes in serum BOP as a function of
serum creatinine were studied with different models. The data
were satisfactorily fitted both by a linear (y = 4.907 X
—0.051;
r = 0.52, P < 0.001) and a parabolic function (y = 16.7 — 2.2 X
+0.632x2; r = 0.54, P < 0.001).
The humoral and histomorphometnc data of the 23 patients
submitted to bone biopsy are reported in Table 2. Sixteen of
these patients had a serum creatinine level> S mg/dl. Serum
creatinine correlated positively with BGP (P < 0.05) and 01 (P
<0.05). But the positive correlations between BGP and 01 (P
<0.001) and AOS (P < 0.01) were stronger (Table 3).
As for the other correlations among humoral and histomor-
phometric parameters (Table 3), 01 and ARS correlated posi-
tively with iPTH and AP. Likewise, AOS correlated positively
with iPTH and AP. OV was correlated positively with AP and
BGP.
Stepwise multiple regression analysis was performed to cor-
relate serum BGP as a dependent variable with the other
biochemical and histomorphometric parameters. The resultant
multiple correlation coefficient (Tm) was 0.836 (P < 0.0001).
BGP serum levels were determined by ARS (serum BGP =5.06
+ 19.25 ARS), while contributions from the other variables
were not statistically significant.
The correlations among biochemical measurements in all
patients are reported in Table 4. Serum levels of BGP correlated
significantly with serum iPTH, AP, and phosphate.
Serum 1 ,25(OH)2D3 was measured in 11 patients before and 1
to 3 months alter beginning of treatment with the D metabolite.
From an average level of 17.4 10.3pg/mi, serum 1,25(OH)2D3
• (132)
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Fig. 2. Serum BGP measurements in normal subjects and in patients
with CRF.
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Table 3. Correlations among biochemical and histomorphometric data in 23 patients with predialytic chronic renal failure
Cr Ca P AP PTH BGP TBV OV Os AOS RS ARS TI0 01
Cr 1.000
Ca .418° 1.000
P .522a —.227 1.000
AP .238 —.079 .183 1.000
PTH .702° —.378 530b .644° 1.000
BGP .466a .051 .239 .786° .662° 1.000
TBV —.167 .257 —.064 .161 .130 .212 1.000
OV .134 —.109 —.286 575' .324 531b .172 1.000
OS .217 —.272 —.272 •473a .366 .423a .074 .917° 1000
AOS .375 —.03 1 .133 •558" 552b 537b .247 537b 597b j()()()
RS .433° —.061 .343 574b 618b .649° .222 577b 544b .705° 1.000
ARS .427° .089 .444° .823c .651c .836° .204 .521° .392 .664° .808° 1.000
TIO —.037 .169 —.312 .497° .185 .502° .320 •777° •570b .425° .379 .456a 1.000
01 .426a .049 .455° .826° .657° .835° .239 .507a .374 634b .827° .990° .427a 1.000
See Methods for histomorphometric abbreviations.â.( 0.05.
b P < 0.01.
'P < 0.001.
Table 4. Correlations among age and the serum biochemical measurements made in 42 patients with CRF
Without 1 ,25(OH)2D3 treatment
AGE BGP PTH AP Cr 1/Cr Ca P
t
.
AGE .0515 .1560 —.0780 .2210 —.2550 —.1440 —.2240
NS NS NS <.05 <.05 NS NS
BGP .2430 .6410 .5800 .5210 —.3610 .1580 .4090
NS <.001 <.001 <.001 <.001 NS <0.001
PTH —.0256 .6769 .2801 .6530 —.4560 — .0770 .3290
NS <.001 <.05 <.001 <.001 NS <0.01
AP m2610 .1654 8 A)490 .0104 -M230
<o:38
Cr — .1992 .3930 .7790 .0990 — .8580 —.0637 .3500
NS <.01 <.001 NS <.001 NS <0.01
1/Cr .1479 .3390 —.6670 —.1894 .9330 .0988 .2160
NS <.05 <.001 N5 <.001 NS NS
Ca —.1000 —.2778 —.3409 .0059 —.2077 .1360 —.1208
NS NS <.05 NS NS NS NS
P —.1390 .0650 .2580 .2270 .3078 —.3900 .1869
NS NS NS NS <.05 <.0! NS
increased to 32.6 9.7 pg/mi during treatment. Average values
of blood calcium and phosphate levels before and after com-
mencement of treatment with I ,25(OH)2D3 were 9.00 0.33
and 9.34 0.50 mg/dl (P < 0.005)for serum calcium and 3.88
0.28 and 4.34 0.71 mg/dl (P < 0.025) for serum phosphate,
respectively. Mean values for serum iPTH, AP, and BGP after
starting 1 ,25(OH)2D3 treatment showed a highly significant fall
(serum iPTH, from 2.65 2.9 to 1.34 0.96 ng/ml, P < 0.005;
AP, from 192.8 110.5 to 123.1 62.9 mU/mi, P < 0.001;
serum BGP, from 23.5 19.8 to 11.22 8.65 ng/ml, P <
0.0001), while serum creatinine levels did not change signifi-
cantly (4.78 2.11 and 5.20 1.80 mg/dl, respectively; NS).
A positive significant correlation between serum BGP and
creatinine levels was also found during treatment with
1,25(OH)2D3 (Fig. 4, Table 4). However, the slope was signifi-
cantly lower (P < 0.0001) than in the untreated state. Serum
BGP levels over the entire range of serum creatinine explored
were lower in the patients treated with 1 ,25(OH)2D3. Figure 5
shows a highly significant correlation (P < 0.001) between BGP
and iPTH during treatment. The slopes of the regression lines of
serum iPTH and BGP values obtained before and during
treatment with 1,25(OH)2D3 are very close, and we conclude
that treatment affects both parameters proportionally. As for
BGP and AP, in spite of a significant decrease during treatment,
they no longer correlated (Table 4).
Figures 6 and 7 show the time course of serum BGP in
patients without treatment and during 1 ,25(OH)2D3 administra-
tion. The correlations of BGP versus time were strongly posi-
tive in ten of 12 untreated patients and negative in ten of 11
patients treated with the vitamin D metabolite. The Mann-
Whitney U test applied to the slopes of treated and untreated
patients showed a highly significant difference (P < 0.001).
Eventual BGP rises (Fig. 7) observed in a few cases were
coincident with terminal renal failure.
Discussion
In recent years, several vitamin K-dependent proteins con-
taining y-carboxyglutamic acid residues have been identified
[18]. The bone GLA protein, which is also measurable in blood,
is an important component of the non-collagen proteins of bone,
and is probably connected with the process of osteoid mineral-
ization. Several studies have supported the hypothesis that
circulating BGP originates from new synthesis, presumably by
the osteoblasts [5], and denied its derivation from the
osteoclastic resorption of bone proteins [19, 20]. Riggs, Tsai,
and Mann [20] have shown that 24-hr i.v. administration of the
synthetic 1-34 fragment of PTH in normal women raised urine
hydroxyproline excretion without any associated change in
serum BGP. Other reports that BGP significantly correlated
with bone mineralization rate, but not with the resorption
parameters [21—23], favor the hypothesis that serum BGP is
connected with the bone formation process. In addition, Price,
Williamson, and Baukol [6] have underlined the relative depen-
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Fig. 6. Time course of serum BGP levels in 12 patients with CRF who
did not receive 1,25(OH)2D3.
dence of BGP synthesis on 1 ,25(OH)2D3 levels. However, a
basal production of the protein was observed even without the
vitamin D metabolite. Increased serum BGP levels have been
reported in primary hyperparathyroidism, as well as in second-
ary hyperparathyroidism of CRF [6, 9, 12]. CRF, at least
starting from a GFR below 30 mllmin [24], is associated with a
deficit of 1 ,25(OH)2D3 [7]. Therefore, serum BGP levels may be
increased in spite of low levels of serum 1 ,25(OH)2D3. On the
other hand, in predialytic [8] and dialytic [23] CRF, no corre-
lation was observed between serum l,25(OH)2D3 and BGP
levels.
Our data confirm the finding of increased serum BGP levels in
CRF [9, 25]. The serum levels of BGP are significantly corre-
lated with serum creatinine. The data were satisfactorily fitted
both by a linear and a parabolic function (Fig. 3). Direct
inspection of the experimental values suggests that the best fit is
given by the non-linear function. From a pathophysiological
point of view, it cannot be excluded that, in the terminal stages
of CRF, serum retention of BGP is faster than that of creatinine.
However, the wide scatter of BGP values for elevated serum
creatinine levels suggests that bone disease may be a more
important determinant of increased BGP levels than the extent
of renal damage per se. This hypothesis seems to be confirmed
by analysis of humoral and histomorphometric data of the 23
patients submitted to bone biopsy.
The increase in BGP is proportional to the increase in serum
iPTH, AP, and phosphate. The progressive increase in iPTH
BGP, ng/m/
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Fig. 4. Correlation between serum BGP and creatinine during
1,25(OH)2D3 treatment (—). The correlation between parameters in
patients without treatment is represented by (---).
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Fig. 5. Correlation between serum BGP and iPTH during 1,25(OH)2D3
treatment (—). The correlation between parameters in untreated pa-
tients is also reported (---).
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serum BGP measurements can replace iPTH in the assessment
-_gdj of hyperparathyroid bone disease.
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levels is clearly the cause of the increased serum BGP. The
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of hyperparathyroidism. Serum BGP falls with iPTH levels
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